Sanofi successfully prices USD 1.5 billion bond issue

PR Newswire/Les Echos/ 
PRESS RELEASE 
         Sanofi successfully prices USD 1.5 billion bond issue 
Paris, France - April 4, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announces
that it has successfully priced its offering of USD 1.5 billion of notes
denominated in US dollars, due April 10, 2018, bearing interest at an annual
rate of 1.25%. 
The offer was made pursuant to Sanofi's shelf registration statement filed with
the US Securities and Exchange Commission on March 11, 2013. 
Sanofi intends to use the net proceeds of the offering for general corporate
purposes, including the repayment of existing borrowings. 
BofA Merrill Lynch, Barclays, Deutsche Bank and J.P Morgan acted as joint
book-running managers for the offering. Credit Agricole CIB, Citi and HSBC 
were co-lead managers for the offering. 
DISCLAIMER
This communication shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or
jurisdiction. 
When available, a written prospectus meeting the requirements of Section 10 of
the US Securities Act of1933, as amended, may be obtained, subject to 
applicable law, from Sanofi, 54, rue la Boétie, 75008, Paris, France. 
This communication is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) high net worth
companies, and other persons to whom it may lawfully be communicated, falling
within Article 49(2)(a) to (d) of the Order (all such persons together being
referred to as "relevant persons"). The notes are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise acquire 
such notes will be engaged in only with, relevant persons. Any person who is 
not a relevant person should not act or rely on this document or any of its
contents. 
No prospectus (including any amendment, supplement or replacement thereto) or
any other offering material has been prepared in connection with the offering 
of the notes that has been approved by the Autorité des marchés financiers or 
by the competent authority of another State that is a contracting party to the
Agreement on the European Economic Area and notified to the Autorité des
marchés financiers; no notes have been offered or sold nor will be offered or
sold, directly or indirectly, to the public in France; the prospectus or any
other offering material relating to the notes have not been distributed or
caused to be distributed and will not be distributed or caused to be 
distributed to the public in France; such offers, sales and distributions have 
been and shall only be made in France to persons licensed to provide the 
investment service of portfolio management for the account of third parties, 
qualified investors (investisseurs qualifiés) other than individuals, in each 
case investing for their own account, all as defined in Articles L. 411-2, 
D. 411-1, D. 744-1, D. 754-1 and D. 764-1 of the French Code monétaire et 
financier. The direct or indirect distribution to the public in France of any 
so acquired notes may be made only as provided by Articles L. 411-1, L. 411-2, 
L. 412-1 and L. 621-8 to L.621-8-3 of the French Code monétaire et financier 
and applicable regulations thereunder. 
Forward-Looking Statements
Any statements made in this communication that are not statements of historical
fact, including statements about Sanofi's beliefs and expectations are
forward-looking statements and should be evaluated as such. Forward-looking
statements include statements that may relate to Sanofi's plans, objectives,
strategies, goals, future events, future revenues or performance, and other
information that is not historical information. Sanofi does not undertake, and
specifically disclaims, any obligation or responsibility to update or amend 
any of the information above except as otherwise required by law. 
Additional Information:
This communication is neither an offer to purchase nor a solicitation of any
offer to sell any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by means of a
prospectus meeting the requirements of the U.S. Securities Act of 1933, as
amended, or an exemption therefrom. 
Contacts: 
Media Relations                Investor Relations
Jean-Marc Podvin               Sébastien Martel
Tel.: + (33) 1 53 77 46 46     Tel.: + (33) 1 53 77 45 45
mr@sanofi.com                  ir@sanofi.com 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Apr/04/2013 07:51 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.